A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

RB/RBAC alternating

"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"

DRUG

RB

"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Kim, Seok Jin

OTHER